Foreign-Trade Zone (FTZ) 7-Mayaguez, Puerto Rico, Authorization of Production Activity, IPR Pharmaceuticals, Inc. (Pharmaceutical Products), Canovanas, Puerto Rico, 37738 [2021-15126]
Download as PDF
<![CDATA[
37738
Federal Register / Vol. 86, No. 134 / Friday, July 16, 2021 / Notices
25, 2021. Rebuttal comments in
response to material submitted during
the foregoing period may be submitted
during the subsequent 15-day period to
September 9, 2021.
A copy of the application will be
available for public inspection in the
‘‘Reading Room’’ section of the FTZ
Board’s website, which is accessible via
www.trade.gov/ftz.
For further information, contact
Qahira El-Amin at Qahira.El-Amin@
trade.gov.
Dated: July 12, 2021.
Andrew McGilvray,
Executive Secretary.
[FR Doc. 2021–15128 Filed 7–15–21; 8:45 am]
BILLING CODE 3510–DS–P
DEPARTMENT OF COMMERCE
Foreign-Trade Zones Board
[B–23–2021]
Foreign-Trade Zone (FTZ) 7—
Mayaguez, Puerto Rico, Authorization
of Production Activity, IPR
Pharmaceuticals, Inc. (Pharmaceutical
Products), Canovanas, Puerto Rico
On March 15, 2021, IPR
Pharmaceuticals, Inc., submitted a
notification of proposed production
activity to the FTZ Board for its facility
within FTZ 7, in Canovanas, Puerto
Rico.
The notification was processed in
accordance with the regulations of the
FTZ Board (15 CFR part 400), including
notice in the Federal Register inviting
public comment (86 FR 15642, March
24, 2021). On July 13, 2021, the
applicant was notified of the FTZ
Board’s decision that no further review
of the activity is warranted at this time.
The production activity described in the
notification was authorized, subject to
the FTZ Act and the FTZ Board’s
regulations, including Section 400.14.
Dated: July 13, 2021.
Andrew McGilvray,
Executive Secretary.
DEPARTMENT OF COMMERCE
International Trade Administration
[C–533–884]
Glycine From India: Preliminary
Results of Countervailing Duty
Administrative Review; 2018–2019
Enforcement and Compliance,
International Trade Administration,
Department of Commerce.
SUMMARY: The Department of Commerce
(Commerce) preliminarily determines
that countervailable subsidies are being
provided to producers and exporters of
glycine from India for the period of
review (POR) September 4, 2018,
through December 31, 2019. The
preliminary net subsidy rates are listed
below in the section titled ‘‘Preliminary
Results of Administrative Review.’’
Interested parties are invited to
comment on these preliminary results.
DATES: Applicable July 16, 2021.
FOR FURTHER INFORMATION CONTACT:
Davina Friedmann, AD/CVD
Operations, Office VI, Enforcement and
Compliance, International Trade
Administration, U.S. Department of
Commerce, 1401 Constitution Avenue
NW, Washington, DC 20230; telephone:
(202) 482–0698.
SUPPLEMENTARY INFORMATION:
AGENCY:
Background
On August 6, 2020, Commerce
published a notice of initiation of
administrative review of the
countervailing duty order on glycine
from India.1 On March 2, 2021,
Commerce extended the deadline for
issuing the preliminary results of
review.2 The revised deadline for these
preliminary results of review is now
June 30, 2021.
For a complete description of the
events that followed the initiation of
this review, see the Preliminary
Decision Memorandum.3 A list of topics
discussed in the Preliminary Decision
Memorandum is included at Appendix
I to this notice. The Preliminary
Decision Memorandum is a public
document and is on file electronically
via Enforcement and Compliance’s
Antidumping and Countervailing Duty
Centralized Electronic Service System
(ACCESS). ACCESS is available to
registered users at https://
access.trade.gov. In addition, a complete
version of the Preliminary Decision
Memorandum can be accessed directly
at https://enforcement.trade.gov/frn/.
Scope of the Order
The merchandise covered by the order
is glycine from India. For a complete
description of the scope of the order, see
the Preliminary Decision Memorandum.
Methodology
Commerce is conducting this review
in accordance with section 751(a)(1)(A)
of the Tariff Act of 1930, as amended
(the Act). For each of the subsidy
programs found countervailable, we
preliminarily determine that there is a
subsidy, i.e., a financial contribution
that gives rise to a benefit to the
recipient, and the subsidy is specific.4
For a full description of the
methodology underlying our
conclusions, see the Preliminary
Decision Memorandum.
On June 11, 2021, we initiated an
investigation of newly alleged subsidy
programs.5 Because we did not receive
information from the Government of
India, Avid Organics Private Limited
(Avid), or Kumar Industries (India)
(Kumar) related to the new subsidy
programs in time to evaluate them for
purposes of these preliminary results of
review, we intend to issue postpreliminary review results that
incorporate these programs.6
Companies Not Selected for Individual
Review
For companies not selected for
individual review, because the 2019
subsidy rates calculated for Avid and
Kumar were above de minimis and not
based on facts available, we have
preliminarily calculated a subsidy rate
based on a weighted-average of the
subsidy rates calculated for Avid and
Kumar using publicly ranged sales data
submitted by respondents.7 For 2018,
we preliminarily assigned to the
companies not individually examined a
subsidy rate of 3.58 percent, which is
the 2018 subsidy rate calculated for
Avid for these preliminary results of
[FR Doc. 2021–15126 Filed 7–15–21; 8:45 am]
1 See Initiation of Antidumping and
Countervailing Duty Administrative Reviews, 85 FR
47731 (August 6, 2020).
2 See Memorandum, ‘‘Glycine from India:
Extension of Time Limit for Preliminary Results,’’
dated March 2, 2021.
3 See Memorandum, ‘‘Decision Memorandum for
the Affirmative Preliminary Determination: First
Administrative Review of Glycine from India,’’
dated concurrently with, and hereby adopted by,
this notice (Preliminary Decision Memorandum).
jbell on DSKJLSW7X2PROD with NOTICES
BILLING CODE 3510–DS–P
VerDate Sep<11>2014
17:26 Jul 15, 2021
Jkt 253001
PO 00000
Frm 00011
Fmt 4703
Sfmt 4703
4 See sections 771(5)(B) and (D) of the Act
regarding financial contribution; section 771(5)(E)
of the Act regarding benefit; and section 771(5A) of
the Act regarding specificity.
5 See Memorandum, ‘‘Administrative Review of
the Countervailing Duty Order on Glycine from
India; 2018–2019, New Subsidy Allegations,’’ dated
June 17, 2021.
6 See Preliminary Decision Memorandum.
7 See Memorandum, ‘‘Calculation of Subsidy Rate
for Non-Selected Companies,’’ dated June 30, 2021.
E:\FR\FM\16JYN1.SGM
16JYN1
]]>Agencies
[Federal Register Volume 86, Number 134 (Friday, July 16, 2021)]
[Notices]
[Page 37738]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2021-15126]
-----------------------------------------------------------------------
DEPARTMENT OF COMMERCE
Foreign-Trade Zones Board
[B-23-2021]
Foreign-Trade Zone (FTZ) 7--Mayaguez, Puerto Rico, Authorization
of Production Activity, IPR Pharmaceuticals, Inc. (Pharmaceutical
Products), Canovanas, Puerto Rico
On March 15, 2021, IPR Pharmaceuticals, Inc., submitted a
notification of proposed production activity to the FTZ Board for its
facility within FTZ 7, in Canovanas, Puerto Rico.
The notification was processed in accordance with the regulations
of the FTZ Board (15 CFR part 400), including notice in the Federal
Register inviting public comment (86 FR 15642, March 24, 2021). On July
13, 2021, the applicant was notified of the FTZ Board's decision that
no further review of the activity is warranted at this time. The
production activity described in the notification was authorized,
subject to the FTZ Act and the FTZ Board's regulations, including
Section 400.14.
Dated: July 13, 2021.
Andrew McGilvray,
Executive Secretary.
[FR Doc. 2021-15126 Filed 7-15-21; 8:45 am]
BILLING CODE 3510-DS-P
